Curcumin improves the paclitaxel induced apoptosis of HPV positive human cervical cancer cells via the NF κB p53 caspase 3 pathway

Experimental and Therapeutic Medicine

Volumn 9, Issue 4, 2015, Pages 1470-1476

  Dang, Yu Ping ^a   Yuan, Xiao Ying ^a   Tian, Rong ^a   Li, Dong Guang ^a   Liu, Wei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Apoptosis; Cervical cancer cells; Curcumin; NF B p53 caspase 3 pathway

Indexed keywords

CASPASE 3; CURCUMIN; FLUORESCEIN ISOTHIOCYANATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PROTEIN E6; PROTEIN E7; PROTEIN P53; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION ASSAY; CELL VIABILITY ASSAY; CERVICAL CANCER CELL LINE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MRNA EXPRESSION ASSAY; MTT ASSAY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOIMMUNOPRECIPITATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; WART VIRUS; WESTERN BLOTTING;

EID: 84922976946     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2240     Document Type: Article

References (53)

1. Bian ML, Cheng JY, Ma L, Cong X, Liu J, Chen Y and Chen X: Evaluation of the detection of 14 high risk human papillomaviruses with HPV 16 and HPV 18 genotyping for cervical cancer screening. Exp Ther Med 6: 1332-1336, 2013.
2. Chao A, Lin CT and Lai CH: Updates in systemic treatment for metastatic cervical cancer. Curr Treat Option Oncol 15: 1-13, 2014.
3. Lu X, Wu L, Liu Z, Xie L and Wang S: Peripheral blood mononuclear cells inhibit proliferation and promote apoptosis of HeLa cells following stimulation with Bacillus Calmette Guerin. Exp Ther Med 5: 561-566, 2013.
4. Distefano M, Fagotti A, Ferrandina G, Fanfani F, Smaniotto D, D'Agostino G, Morganti A and Scambia G: Preoperative chemoradiotherapy in locally advanced cervical cancer: long term outcome and complications. Gynecol Oncol 99 (3 Suppl 1): S166-S170, 2005.
5. Kjellström J, Oredsson SM and Wennerberg J: Increased toxicity of a trinuclear Pt compound in a human squamous carcinoma cell line by polyamine depletion. Cancer Cell Int 12: 20, 2012.
6. Kanamori Y, Kigawa J, Minagawa Y, Irie T, Itamochi H, Cheng X, Okada M and Terakawa N: Clinical responses and platinum concentrations in tumors after intra arterial and intravenous administration of cisplatin in the same patients with cervical cancer. Gynecol Obstet Invest 44: 57-60, 1997.
7. Sun XY, Zheng YP, Lin DH, Zhang H, Zhao F and Yuan CS: Potential anti cancer activities of furanodiene, a sesquiterpene from Curcuma wenyujin. Am J Chin Med 37: 589-596, 2009.
8. Grundmann O, Fillinger JL, Victory KR, Burd R and Limesand KH: Restoration of radiation therapy induced salivary gland dysfunction in mice by post therapy IGF 1 administration. BMC cancer 10: 417, 2010.
9. Termrungruanglert W, Kudelka AP, Piamsomboon S, Edwards CL, Verschraegen CF, Loyer E and Kavanagh JJ: Remission of recurrent cervical cancer with paclitaxel and carboplatin: a case report and review of literature. Eur J Gynaecol Oncol 17: 493-496, 1996.
10. Zanetta G, Fei F and Mangioni C: Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. Semin Oncol 27: 23-27, 2000.
11. Braicu EI, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kummel S, Stamatian F, Yalcinkaya I, Mentze M, Lichtenegger W and Sehouli J: Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO AGO phase III adjuvant trial of simultaneous cisplatin based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy. Cytokine 61: 755-758, 2013.
12. Sreekanth CN, Bava SV, Sreekumar E and Anto RJ: Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene 30: 3139-3152, 2011.
13. Lee KH, Yim EK, Kim SJ, Namkoong SE, Um SJ and Park JS: Proteomic analysis of anti cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol 98: 45-53, 2005.
14. Park DC, Yeo SG, Shin EY, Mok SC and Kim DH: Clusterin confers paclitaxel resistance in cervical cancer. Gynecol Oncol 103: 996-1000, 2006.
15. Kuo DY, Blank SV, Christos PJ, Kim M, Caputo TA, Pothuri B, Hershman D, Goldman N, Ivy PS, Runowicz CD, Muggia F, Goldberg GL and Einstein MH: Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study. Gynecol Oncol 116: 442-446, 2010.
16. Saito I, Kitagawa R, Fukuda H, Shibata T, Katsumata N, Konishi I, Yoshikawa H and Kamura T: A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic cancer study group/Japan clinical oncology group study (JCOG0505). Jpn J Clin Oncol 40: 90-93, 2010.
17. Kosmas C, Mylonakis N, Tsakonas G, Vorgias G, Karvounis N, Tsavaris N, Daladimos T, Kalinoglou N, Malamos N, Akrivos T and Karabelis A: Evaluation of the paclitaxel ifosfamide cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer. Br J Cancer 101: 1059-1065, 2009.
18. Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, Spannuth WA and Gold MA: A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 105: 299-303, 2007.
19. Karaman M, Firinci F, Cilaker S, Uysal P, Tugyan K, Yilmaz O, Uzuner N and Karaman O: Anti inflammatory effects of curcumin in a murine model of chronic asthma. Allergol Immunopathol (Madr) 40: 210-214, 2012.
20. Jacob JN, Badyal DK, Bala S and Toloue M: Evaluation of the in vivo anti inflammatory and analgesic and in vitro anti cancer activities of curcumin and its derivatives. Nat Prod Commun 8: 359-362, 2013.
21. Sreenivasan S and Krishnakumar S: Synthestic effect of curcumin in combination with Anticancer agents in human retinoblastoma cancer cells lines. Curr Eye Res 11:1-13, 2014.
22. Basnet P and Skalko Basnet N: Curcumin: an anti inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 16: 4567-4598, 2011.
23. Bava SV, Sreekanth CN, Thulasidasan AK, Anto NP, Cheriyan VT, Puliyappadamba VT, Menon SG, Ravichandran SD and Anto RJ: Akt is upstream and MAPKs are downstream of NF kappaB in paclitaxel induced survival signaling events, which are down regulated by curcumin contributing to their synergism. Int J Biochem Cell Biol 43: 331-341, 2011.
24. Hossain M, Banik NL and Ray SK: Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int 61: 1102-1113, 2012.
25. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D and Anto RJ: Sensitization of taxol induced apoptosis by curcumin involves down regulation of nuclear factor kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280: 6301-6308, 2005.
26. Boztas AO, Karakuzu O, Galante G, Ugur Z, Kocabas F, Altuntas CZ and Yazaydin AO: Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells. Mol Pharm 10: 2676-2683, 2013.
27. Brem GJ, Mylonas I and Brüning A: Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression. Gynecol Oncol 128: 383-390, 2013.
28. Skiles ML, Sahai S and Blanchette JO: Tracking hypoxic signaling within encapsulated cell aggregates. J Vis Exp 58: 3521, 2011.
29. Li GL, Jiang W, Xia Q, Chen SH, Ge XR, Gui SQ and Xu CJ: HPV E6 down regulation and apoptosis induction of human cervical cancer cells by a novel lipid soluble extract (PE) from Pinellia pedatisecta Schott in vitro. J Ethnopharmacol 132: 56-64, 2010.
30. Jackson R, Togtema M and Zehbe I: Subcellular localization and quantitation of the human papillomavirus type 16 E6 oncoprotein through immunocytochemistry detection. Virology 435: 425-432, 2013.
31. Arroyo M, Bagchi S and Raychaudhuri P: Association of the human papillomavirus type 16 E7 protein with the S phase specific E2F cyclin A complex. Mol Cell Biol 13: 6537-6546, 1993.
32. Goel A and Aggarwal BB: Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62: 919-930, 2010.
33. Tan S, de Vries EG, van der Zee AG and de Jong S: Anticancer drugs aimed at E6 and E7 activity in HPV positive cervical cancer. Curr Cancer Drug Targets 12: 170-184, 2012.
34. Kim MS, Bak Y, Park YS, Lee DH, Kim JH, Kang JW, Song HH, Oh SR and Yoon DY. Wogonin induces apoptosis by suppressing E6 and E7 expressions and activating intrinsic signaling pathways in HPV 16 cervical cancer cells. Cell Biol Toxicol 29: 259-272, 2013.
35. Zhou J, Li B, Peng C, Wang F, Fu Z, Zhou C, Hong D, Ye F, Lü W and Xie X: Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral vector mediated shRNA targeting the common promoter of HPV16-E6 and E7 oncogenes. Antiviral Res 98: 305-313, 2013.
36. Teissier S, Ben Khalifa Y, Mori M, Pautier P, Desaintes C and Thierry F: A new E6/P63 pathway, together with a strong E7/E2F mitotic pathway, modulates the transcriptome in cervical cancer cells. J Virol 81: 9368-9376, 2007.
37. Chiu TH, Lan KY, Yang MD, Lin JJ, Hsia TC, Wu CT, Yang JS, Chueh FS and Chung JG: Diallyl sulfide promotes cell cycle arrest through the p53 expression and triggers induction of apoptosis via caspase and mitochondria dependent signaling pathways in human cervical cancer Ca Ski cells. Nutr Cancer 65: 505-514, 2013.
38. Zhou X, Gu Y and Zhang SL: Association between p53 codon 72 polymorphism and cervical cancer risk among Asians: a HuGE review and meta analysis. Asian Pac J Cancer Prev 13: 4909-4914, 2012.
39. Vidya Priyadarsini R, Senthil Murugan R, Maitreyi S, Ramalingam K, Karunagaran D and Nagini S: The flavonoid quercetin induces cell cycle arrest and mitochondria mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF κB inhibition. Eur J Pharmacol 649: 84-91, 2010.
40. Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu FF, Mackay H, Amir E and Liu G: p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta analysis. Clin Cancer Res 18: 6407-6415, 2012.
41. Shi M, Du L, Liu D, Qian L, Hu M, Yu M, Yang Z, Zhao M, Chen C, Guo L, Wang L, Song L, Ma Y and Guo N: Glucocorticoid regulation of a novel HPV E6 p53 miR 145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol 228: 148-157, 2012.
42. Ristriani T, Fournane S, Orfanoudakis G, Travé G and Masson M: A single codon mutation converts HPV16-E6 oncoprotein into a potential tumor suppressor, which induces p53 dependent senescence of HPV positive HeLa cervical cancer cells. Oncogene 28: 762-772, 2009.
43. Fiedler M, Müller Holzner E, Viertler HP, Widschwendter A, Laich A, Pfister G, Spoden GA, Jansen Dürr P and Zwerschke W: High level HPV 16 E7 oncoprotein expression correlates with reduced pRb levels in cervical biopsies. FASEB J 18: 1120-1122, 2004.
44. Loignon M and Drobetsky EA: The initiation of UV induced G(1) arrest in human cells is independent of the p53/p21/pRb pathway but can be attenuated through expression of the HPV E7 oncoprotein. Carcinogenesis 23: 35-45, 2002.
45. Hu T, Ferril S, Snider A and Barbosa M: In vivo analysis of HPV E7 protein association with pRb, p107 and p130. Int J Oncol 6: 167-174, 1995.
46. Liu WL, Green N, Seymour LW and Stevenson M: Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma. Cancer Gene Ther 16: 764-775, 2009.
47. Johnson RF and Perkins ND: Nuclear factor kappaB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect. Trends Biochem Sci 37: 317-324, 2012.
48. Sun Y, Holley AK and St Clair DK: p53 regulation of energy metabolism and mitochondria regulation of p53 in cancer cells: an insight into the role of manganese superoxide dismutase. Curr Pharm Biotechnol 14: 261-273, 2013.
49. Galluzzi L, Morselli E, Kepp O, Tajeddine N and Kroemer G: Targeting p53 to mitochondria for cancer therapy. Cell Cycle 7: 1949-1955, 2008.
50. Yim EK, Tong SY, Ho EM, Bae JH, Um SJ and Park JS: Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells. Oncol Rep 21: 549-557, 2009.
51. Prasad S, Ravindran J and Aggarwal BB: NF kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 336: 25-37 2010.
52. Ferris RL and Grandis JR: NF kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res 13: 5663-5664, 2007.
53. Sen T, Dutta A and Chatterjee A: Epigallocatechin-3-gallate (EGCG) downregulates-B (MMP-9) by involvement of FAK/ERK/NFkappa B and AP-1 in the human breast cancer cell line MDA-MB-231. Anticancer Drug 21: 632-644, 2010.